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Abstract
Purpose A growing body of preclinical and observational research suggests that statins have potential as a therapeutic strategy in
patients with cancer. This systematic review of randomised controlled trials (RCTs) in patients with solid tumours aimed to
determine the efficacy of statin therapy on mortality outcomes, their safety profile and the risk of bias of included studies.
Methods Full-text articles comparing statin therapy versus control in solid tumours and reporting mortality outcomes were
identified from Medline and Embase from conception to February 2020. A systematic review with qualitative (primarily) and
quantitative synthesis was conducted. This systematic review was prospectively registered (Prospero registration
CRD42018116364).
Results Eleven trials of 2165 patients were included. Primary tumour sites investigated included lung, colorectal, gastro-oesoph-
ageal, pancreatic and liver. Most trials recruited patients with advanced malignancy and used sub-maximal statin doses for
relatively short durations. Aside from one trial which demonstrated benefit with allocation to pravastatin 40 mg in hepatocellular
carcinoma, the remaining ten trials did not demonstrate efficacy with statins. The pooled hazard ratio for all-cause mortality with
allocation to pravastatin in patients with hepatocellular carcinoma in two trials was 0.69 (95% confidence interval CI 0.30–1.61).
Study estimates were imprecise. There were no clinically important differences in statin-related adverse events between groups.
Overall, included trials were deemed low risk of bias.
Conclusion The trial evidence is not sufficiently robust to confirm or refute the efficacy and safety of statins in patients with solid
malignant tumours. Study and patient characteristics may explain this uncertainty. The potential role of high-dose statins in
adjuvant settings deserves further research.
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C Cisplatin
DCR Disease control rate
DDD Defined daily dose
DX Dexamethasone
ECOG Eastern Cooperative
Oncology Group
E Epirubicin
ET Etoposide
FOLFIRI 5-Fluorouracil and irinotecan
GC Gemcitabine
GOJ Gastro-oesophageal junction
GF Gefitinib
HMG-CoA Hydroxy-3-methylglutaryl-CoA
OS Overall survival
Md Median
Me Mean
Mx Maximum
NA Non-adenocarcinomatous
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00228-020-02967-0) contains supplementary
material, which is available to authorized users.
* Leo Alexandre
leo.alexandre@uea.ac.uk
1 Norwich Medical School, University of East Anglia, Norwich NR4
7TJ, UK
2 Department of Gastroenterology, Norfolk and Norwich University
Hospital, Norwich NR47UY, UK
European Journal of Clinical Pharmacology
https://doi.org/10.1007/s00228-020-02967-0
NS Not stated
PRISMA Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
PFS Progression-free survival
Rad R Radiological response
RR Response rate
RCT Randomised controlled trial
TACE Transcatheter arterial chemoembolisation
TTP Time to progression
THL Thalidomide
X Capecitabine
XELIRI regimen Capecitabine plus irinotecan
Background
Hydroxy-3-methylglutaryl-CoA (HMG-CoA) inhibitors, bet-
ter known as statins, are a class of lipid-lowering agents that
are highly effective and used widely in clinical practice for the
primary and secondary prevention of cardiovascular disease
[1]. Statins inhibit the rate-limiting step of the mevalonate
pathway, a ubiquitous metabolic cascade which plays an es-
sential role in the synthesis of downstream sterol (e.g. choles-
terol) and non-sterol isoprenoids [2]. There is growing evi-
dence that a number of these biologically active intermediates
exert functions which have direct relevance to cancer biology,
with roles in proliferative signalling, cell-cycle regulation, an-
giogenesis, and metastases [3]. Interest in the potential of
statins to prevent and treat cancer has grown over the last three
decades.
In vitro studies have demonstrated that statins inhibit pro-
liferation, induce apoptosis and limit invasiveness in numer-
ous malignancies, and have demonstrated the functional rele-
vance of mevalonate pathway intermediates in these observa-
tions [4–6].Mutant TP53, themost frequentlymutated gene in
cancer [7, 8] and consistently associated with poor prognosis
[9], has been shown to upregulate transcription of mevalonate
pathway products to sustain malignant proliferation [10], a
pathway potently inhibited by statins. Furthermore, statins
have been shown to selectively destabilise mutant TP53 pro-
tein [11]. Preclinical in vivo studies have demonstrated statins
effectively inhibit growth of established tumours with no no-
ticeable effect on normal tissues [11, 12]. These preclinical
observations underscore the potential for statins as a viable
therapeutic strategy in human malignancy.
The most recent systematic review of observational re-
search included 95 cohorts with over 1.1 million cancer pa-
tients and demonstrated post-diagnostic statin use was associ-
ated with a significant reduction in all-cause mortality (HR
0.70, 95% CI 0.66–0.74 pooled from 55 studies), with broadly
similar effect sizes for progression-free survival, cancer-
specific mortality and disease-free survival [13]. However,
to varying degrees, studies were potentially susceptible to
selection bias, immortal-time bias and confounding.
Nevertheless, compared with studies with a higher risk of bias
(≤ 8 points on a 6-item scale [14]), effect sizes of those with a
lower risk of bias (> 8 points) were attenuated, however
remained statistically significant. While preclinical and epide-
miological evidence is encouraging, causality remains to be
established. To determine whether statins are an effective ther-
apeutic option for specific cancers, evidence from well-de-
signed, sufficiently powered, randomised controlled trials
(RCTs) are required.
A series of trials have assessed the efficacy and safety of
statins in patients with solid tumours; however, there remains
considerable uncertainty, and the justification for further trials
has been questioned [15]. The conduct of future trials should
be reliably informed by critical appraisal of existing
randomised studies in patients with cancer. Therefore, we un-
dertook a systematic review of statins in patients with any
malignancy to assess the current state of evidence from
RCTs. Specifically, in patients with solid tumours, we aimed
to determine (i) the efficacy of statin therapy on mortality
outcomes, (ii) the safety profile of statins, and (iii) the risk of
bias in RCTs of statin therapy.
Methods
This systematic review was registered (CRD42018116364)
on the PROSPERO database and conducted in accordance
with the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines [16].
Search strategy
We sought relevant published articles by searching
MEDLINE (1948 onwards) and Embase (1980 onwards)
(Supplementary Table 1) using the OVID interface and man-
ual searches of reference lists of any systematic reviews iden-
tified by the previous step. We used the following search
terms to search each database: hydroxymethylglutaryl-CoA
reductase inhibitors, statin, cancer, carcinoma, neoplasms,
malignancy and randomised controlled trial. The literature
search was limited to the English language and human sub-
jects. Searches were completed in Feb 2020.
Eligibility criteria
Only RCTs satisfying the following eligibility criteria were
included in the systematic review: (i) statin therapy was the
intervention, either given alone or in combination with a co-
intervention across trial arms; (ii) at least one trial group re-
ceived placebo, no statin or standard care alone; (iii) partici-
pants were diagnosed with a malignant solid tumour prior to
enrolment; and (iv) overall survival (OS), progression-free
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survival (PFS) or response rate (RR) were reported outcomes.
No restrictions were placed on the statin administered,
posology, frequency or duration of administration. No restric-
tions were placed on length of follow-up. Two reviewers (JPT
and LA) independently screened abstracts and selected full-
text articles for inclusion based on the above criteria.
Discrepancies were resolved through discussion among two
or more reviewers.
Data extraction and quality assessment
Two reviewers (JPT and LA) independently extracted data
from each selected article for study characteristics (location,
setting, number of randomised patients, recruitment period,
primary cancer site, intervention, duration of statin therapy,
concomitant therapy and reported outcome measures); patient
characteristics at enrolment (number of patients allocated to
active and control groups, age, gender, cancer stage and
Eastern Cooperative Oncology Group [ECOG] performance
status); study outcomes (reported median overall and
progression-free survival in allocated groups with correspond-
ing hazard ratios (and confidence intervals) and reported re-
sponse rates (%) in each group); and toxicity profile. For con-
tinuous participant characteristics and outcomes, we extracted
means (with corresponding standard deviations) and medians
(with corresponding ranges) as appropriate in each arm. To
assist the comparison of statin type and posology used be-
tween studies, the defined daily dose (DDD) for each trial
was calculated [17]. The DDD is a standardised measure of
drug exposure relative to the assumed average maintenance
dose per day for a drug used, for its main indication in adults
was as defined by the World Health Organization. For exam-
ple, a single dose of simvastatin 30mg or atorvastatin 20mg is
equivalent to 1 DDD. Two reviewers (JPT and LA) used the
Cochrane risk of bias tool to assess internal validity of each
eligible study across seven items: random sequence genera-
tion, allocation concealment, blinding of participants and per-
sonnel, blinding of outcome assessment, incomplete outcome
data, selective reporting and other sources of bias [18]. Given
the outcomes of interest were objective (e.g. all-cause mortal-
ity), open-label study designs, where applicable, were deemed
to pose minimal risk of bias for the domains of “blinding of
participants and personnel”, and “blinding of outcome assess-
ment”. Discrepancies were resolved through consensus dis-
cussion between reviewers. We contacted authors for addi-
tional information where required.
Study outcomes
The primary outcome was overall survival (OS), defined as
the time from randomisation to death from any cause [19].
Secondary outcomes were (i) progression-free survival
(PFS), defined as time from randomisation to first observed
cancer progression or death; (ii) response rate (RR), defined as
the proportion of patients with tumour size reduction of a
predefined amount and for a minimum time period [19]; and
(iii) toxicity (proportions of grade 3–5 and separately statin-
related adverse events in each group).
Statistical analysis
From the outset, we decided it would be inappropriate to con-
duct a quantitative meta-analysis comprising trials with differ-
ent primary cancers as any resultant summary effect size esti-
mate for mortality outcomes would be difficult to interpret.
This is because each distinct cancer has disparate biology,
behaviour, prognosis, treatments and responsiveness to thera-
py. Furthermore, while the mevalonate pathway is ubiquitous
to all eukaryotes and will be functional in malignancy, there is
insufficient evidence at present to suggest a universally con-
sistent role in effecting cancer prognosis. As a result, we pri-
marily undertook a qualitative assessment of included trials to
critically review the study characteristics, participant charac-
teristics, mortality and safety outcomes of eligible studies. We
performed a quantitative meta-analysis, where possible, of
any trials in patients with the same primary cancer.
Summary study characteristics were calculated and weighted
by sample size for gender, cancer stage and ECOG performance
status.Where p valueswere not provided in original study reports
for comparisons between intervention and control arm for overall
response rate, we calculated these with extracted categorical data
using the chi-squared test or Fisher’s exact test, as appropriate.
Meta-analysis of trials involving patients with the same primary
cancer was performed to quantify the association between statin
use and overall survival. Effect estimates were pooled by the
inverse of their variance and are presented as pooled hazard ratios
(HRs)with corresponding 95%CIs. Due to differences in recruit-
ed study populations, concomitant therapies and intervention
protocols, we utilised a random-effects meta-analysis using the
method of DerSimonian and Laird [20]. Heterogeneity was esti-
mated using the Cochrane’s Q and I2 statistics. A two-tailed p
value of less than 0.05 was defined as statistically significant for
all analyses apart fromCochrane’sQ test for heterogeneitywhere
a p value of 0.10 was selected as the threshold of significance.
Results of this meta-analysis were illustrated bymeans of a forest
plot. Analyses were performed with STATA version 15.1
(StataCorp LP, College Station, TX, USA).
Results
Search and selection of studies
Among 1008 articles identified from the literature search, 15
full-text articles were assessed for eligibility, of which eleven
were ultimately eligible for inclusion (Fig. 1) [21–31]. The
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four excluded articles met all inclusion criteria except for the
outcomes of interest, instead focusing on surrogate outcomes
[32–35].
Study characteristics
The characteristics of selected studies are shown in Table 1.
Four were phase III studies [22, 24, 26, 27] and the remainder
were phase II/pilot/feasibility trials. Of the eleven RCTs, six
originated from East Asia [23, 26–29, 31]. Four studies were
performed in Europe [21, 22, 24, 30] and one in Egypt [25].
All studies were conducted in hospital-based settings. In total,
2165 participants were recruited across all trials. Four studies
were conducted at a single site and included between 30 and
106 participants [25, 29–31]. The largest trial included 846
patients (LUNGSTAR) across 91 UK centres [24]. The
gastro-intestinal tract and accessory digestive organs were
the primary site examined in seven trials, including cancers
of the gastro-oesophageal junction/stomach [27, 30],
oesophagus/gastro-oesophageal junction [21], pancreas [26],
liver [22, 31] and colorectum [26]. The remaining studies
separately recruited patients with small cell lung cancer [24],
non-small cell lung cancer [23, 29] and brain metastases (with
various primary tumour sites) [25]. Eight of the trials explic-
itly excluded prior/current statin users [21, 22, 24–26, 28–30],
and no trials reported the proportion of prior/current users
among the randomised population. The intervention arm in
seven studies was simvastatin [21, 23, 25–29] and in four
studies was pravastatin [22, 24, 30, 31]. The highest DDD
used in one study was 2.67 [25] and in the remaining ten
studies was 1.33. Open-label statins were administered in six
studies [22, 23, 25, 29–31], and identical matched placebo
was used in those remaining. Reported median duration of
statin therapy administration was 3–8.6 months [22, 24, 26,
27, 29]. One trial of pravastatin in hepatocellular carcinoma
administered statins for a mean of 16.5 months [31].
Concomitant chemo/radiotherapy was administered in all but
one trial [21].
Patient characteristics
The mean age of recruited participants between trials was
between 53 and 68 years (Supplementary Table 2) and was
generally well balanced between groups. Of all recruited par-
ticipants, 64.5% were male. Gender was generally well bal-
anced between groups; however, there were numerical differ-
ences (≥ 10%) for three small trials [23, 25, 30]. All but one
trial [21] included patients with metastatic disease at enrol-
ment. Eight trials reported exact proportions with metastatic
disease [21, 22, 24, 26–29, 31], comprising 2035 recruited
participants, of which 65% had metastases (Table 2).
Disease staging appeared well balanced between groups. Of
nine trials which reported ECOG performance status [21, 22,
24, 26–30], including 2032 patients, 87%were status 0–1, and
13% were status 2–3. ECOG performance status appeared
well balanced between groups.
Mortality outcomes
Two trials investigated the effect of pravastatin 40 mg in pa-
tients with advanced hepatocellular carcinoma [22, 31].
Allocation to pravastatin therapy was associated with signifi-
cantly improved overall survival in one of these studies only
[31]: median survival was 18 months in the pravastatin group
and 9 months in the control group (HR 0.42, 95% CI 0.20–
0.83). Meta-analysis of overall survival with pravastatin in
both these trials revealed a HR of 0.69 (95% CI: 0.30–1.61)
which was not statistically significant (p = 0.392)
(Supplementary Fig. 1). The Cochrane Q test (p = 0.024)
and I2 statistic (80.5%) demonstrated a statistically significant
degree of heterogeneity (p < 0.10). None of the other included
trials demonstrated significant improvements in overall sur-
vival with statins, including for small-cell lung cancer, non-
small cell lung cancer, oesophageal/GOJ/gastric cancers, co-
lorectal cancer and pancreatic cancer. No improvements in
progression-free survival were observed with allocation to
statins individually in nine studies (n = 2050) in which this
outcome was reported [22–30]. There were no significant dif-
ferences in overall response rate for the eight studies (n =
1727) reporting this outcome [23–30].
Safety profile
Five trials reported grades 3–5 adverse events. None of these
trials demonstrated significant differences in grades 3–5 ad-
verse events between statin and control group (n = 1497) out-
come [21, 24, 26, 27, 29] (Supplementary Table 3). Statin-
related adverse events (myalgia/myopathy or abnormal ala-
nine aminotransferase/aspartate aminotransferase or elevated
creatine phosphokinase) were similar in proportion between
groups in all nine studies reporting these outcomes [21–28,
30]. Most trials had small sample sizes and may have been
inadequately powered to detect clinically relevant differences
in adverse events if they existed (Table 3).
Risk of bias
Figure 2 shows the assessment of risk of bias in the included
trials as per the Cochrane risk of bias tool, illustrated using the
robvis application [36]. Four trials reported random sequence
generation and allocation concealment adequately [21, 24, 26,
28], while this was insufficiently reported in the remaining
seven. While six trials were open-label studies, any deviations
from intended intervention were unlikely to impact on the
outcome and therefore were deemed at low risk of perfor-
mance bias [22, 23, 25, 29–31]. Risk of detection bias for all
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trials overall was determined to be low given that knowledge
of statin allocation (where applicable to open-label studies)
would seem unlikely to bias reported outcomes not involving
subjective judgement, such as mortality outcomes or measures
of treatment response. All trials were deemed to be at low risk
of selective reporting.
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Fig. 2 Risk of bias of selected studies using the Cochrane risk of bias tool
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Discussion
In summary, this systematic review included eleven trials of
statin therapy in 2165 patients with solid tumours in total,
including small cell lung cancer (n = 846), non-small cell lung
cancer (n = 106 and n = 68), colorectal cancer (n = 269), gas-
tric adenocarcinoma (n = 244 and n = 30), oesophageal adeno-
carcinoma (n = 32), pancreatic cancer (n = 114), hepatocellu-
lar cancer (n = 83 and n = 323) and patients with brain metas-
tases (from mainly breast and lung primaries) (n = 50). Most
patients recruited had advanced malignancy and received con-
comitant palliative chemotherapy. Most patients received
40 mg of simvastatin or pravastatin (1.33 DDD), and typically
for short durations (on average fewer than 9 months). Most
trials did not demonstrate significant improvements in overall
survival (aside from one trial of pravastatin 40 mg in hepato-
cellular carcinoma [31]), and no trials reported improvements
in progression-free survival or overall response rate. Meta-
analysis of the two trials involving pravastatin 40 mg in ad-
vanced hepatocellular cancer [22, 31] revealed no significant
improvements in overall survival (Supplementary Fig. 1).
There was no indication in any trial of an increased rate of
adverse events in those allocated to statins. Overall, included
trials were deemed to be at low risk of bias using the Cochrane
risk of bias tool [18].
Comparison with previous work
This is the second systematic review of RCTs to examine both
the clinical efficacy and safety profile of statins in patients
with solid tumours. The first included a meta-analysis of eight
RCTs included in this systematic review [37]. This review
provided a brief description of study characteristics and the
overwhelming focus was on quantitative synthesis of the ef-
fect of statins on OS, PFS, RR and adverse events. In contrast,
our review is primarily a qualitative synthesis of included
trials and provides more detail regarding important character-
istics relating to included studies (country, blinding, duration
of statin therapy, DDD) and participants (demography, cancer
staging, performance status) to aid interpretation. Another
more recent systematic review focused on a meta-analysis of
nine of the included RCTs in our review to examine the effect
of allocation to statins on OS and PFS [38]. As previously
stated, we deliberately did not conduct a meta-analysis of all
RCTs given irreconcilable heterogeneity of included studies
and uncertainty surrounding the assumption of a uniform
treatment effect, with resultant difficulties in interpretation of
summary estimates.
The cholesterol treatment trialists’ collaboration individual
patient data (IPD) meta-analysis of 22 RCTs of statin vs. con-
trol (primary or secondary prevention of cardiovascular dis-
ease, n = 134,537) and 5 RCTs of high-dose vs. low-dose
statins (secondary prevention, n = 39,612) demonstrated no
evidence of reduced incident cancer overall (RR 1.00, 95%
CI 0.96–1.04) or related cancer-specific mortality (RR 0.98,
95% CI 0.92–1.05) for those allocated to the active arm [39].
No significant associations for mortality were demonstrated
individually for any of the 23 primary sites examined.
However, only cancers diagnosed after randomisation were
considered (1.4% developed cancer per year after
randomisation), and it is not clear how many of these patients
were receiving study drug from the point of cancer diagnosis.
It is therefore difficult to make inferences of the effect of
allocation to statins on mortality outcomes in patients with
cancer from this IPD meta-analysis.
Limitations
It is possible that statins do not exert clinically relevant effects
in patients with solid tumours; however, other explanations
for the divergence of trial evidence from the promising pre-
clinical and epidemiological data deserve consideration. Of
included studies, only four were phase III studies, and the
remaining seven were not powered to detect significant differ-
ences in mortality outcomes. Of the phase III studies, three
[22, 26, 27] were powered to detect relatively large effect sizes
(HR 0.74, HR 0.65, and HR 0.67 respectively) and were at
risk of type II error should the actual effect sizes have been
more conservative. The largest trial to date in small cell lung
cancer (n = 846) was powered to detect a HR of 0.82 [24].
Treatment response to statins could feasibly differ between
palliative and adjuvant settings, depending on their primary
mechanism of action in individual tumour types (for example,
a primary effect on inhibition of metastases as seen in colo-
rectal cancer may favour response in the adjuvant setting [40])
and the influence of baseline tumour burden. All but one trial
included patients with metastatic disease at baseline (65% of
participants overall where reported); in such patients with
poor prognosis in receipt of statins for short durations, pre-
cluding a marked cytotoxic effect of statins (which would
seem unlikely), it may not be possible to elicit or demonstrate
treatment response. Furthermore, it is difficult to generalize
these trial findings to the adjuvant setting. Although an effec-
tive statin dose has yet to be defined in the setting of cancer
therapy, and may differ from the licenced doses prescribed for
the prevention of cardiovascular disease, the dose of statins
assessed in these trials may have been insufficient. All trials
used statins at sub-maximal doses (ten with a DDD of 1.33
and one with a DDD of 2.67); higher doses (e.g. atorvastatin
80 mg—DDD 4) are clinically licenced in cardiovascular pre-
vention [41] and could be investigated in a trial. Stratification
of effect sizes according to statin type, dose (as defined by
DDD) and intended duration of therapy may have been infor-
mative; however, such comparisons would have included tri-
als with different primary sites in each strata, and the resulting
Eur J Clin Pharmacol
estimates and tests for interaction would have been difficult to
interpret. It is unclear whether statin use prior to
randomisation is an effect modifier for the association be-
tween statin allocation and mortality outcomes, as most stud-
ies excluded prior/current statin use; and those studies which
did not specifically exclude such users did not report the pro-
portion of existing users in the randomised population.
Recommendations
Given the imprecise estimates for efficacy and the limitations
of previous trials discussed above, the current trial evidence
base does not preclude the conduct of future statin trials in
patients with solid malignancies. Further definitive phase III
trials are required to determine the efficacy and safety profile
of statins in individual tumour types, provided there exists
sufficient scientific justification for their conduct: including
the proposed mechanism of action applicable to underlying
tumour biology and the relevance of the pharmacokinetic
properties of the selected statin. High-dose statin therapy
should be considered tomaximize the probability of observing
clinically relevant effects: given the dose-dependent effects of
statins in pre-clinical research [42] and trial data for their cur-
rent licenced indications [41]. Future trials should be ade-
quately powered to detect more conservative effect sizes than
previously examined; indeed, relatively small clinically sig-
nificant differences in primary outcomes may be justifiable
given that statins are easily administered, low-cost medica-
tions with a favourable safety profile when used for their li-
cenced indications [43]. Investigators should consider the
merits of investigating statins in the adjuvant setting, where
there is mounting pre-trial evidence [44]. Future trials should
ideally collect blood and fresh frozen tissue to permit transla-
tional research studies including biomarkers predictive of
treatment response.
Conclusions
Overall, the trial evidence is not sufficiently robust to confirm
or refute the efficacy and safety of statins in addition to the
current standard of care in patients with solid malignant tu-
mours. Most trials were not adequately powered to detect
more conservative differences in efficacy outcomes, and
statins were administered for short durations at submaximal
doses in patients with predominantly advanced malignancy.
Based on this evidence, it may be premature to disregard a
potential beneficial role of statins in cancer therapy and there
is insufficient evidence to preclude the conduct of future trials.
The potential role of high-dose statins in adjuvant settings
deserves further research.
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